Axsome Therapeutics Inc [AXSM] stock is trading at $123.47, up 1.81%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The AXSM shares have gain 6.16% over the last week, with a monthly amount glided 19.85%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, Oppenheimer started tracking the stock with Outperform rating on June 03, 2025, and set its price target to $185. On April 07, 2025, Jefferies initiated with a Buy rating and assigned a price target of $200 on the stock. Deutsche Bank started tracking the stock assigning a Buy rating and suggested a price target of $176 on February 11, 2025. Mizuho reiterated its recommendation of a Outperform and reduced its price target to $122 on December 31, 2024. Wells Fargo started tracking with a Overweight rating for this stock on September 03, 2024, and assigned it a price target of $140. In a note dated August 06, 2024, BofA Securities upgraded a Buy rating on this stock and boosted its target price from $95 to $106.
Axsome Therapeutics Inc [AXSM] stock has fluctuated between $75.56 and $139.13 over the past year. Currently, Wall Street analysts expect the stock to reach $189 within the next 12 months. Axsome Therapeutics Inc [NASDAQ: AXSM] shares were valued at $123.47 at the most recent close of the market. An investor can expect a potential return of 53.07% based on the average AXSM price forecast.
Analyzing the AXSM fundamentals
Axsome Therapeutics Inc [NASDAQ:AXSM] reported sales of 495.03M for the trailing twelve months, which represents a growth of 72.13%. Gross Profit Margin for this corporation currently stands at 0.91% with Operating Profit Margin at -0.46%, Pretax Profit Margin comes in at -0.5%, and Net Profit Margin reading is -0.5%. To continue investigating profitability, this company’s Return on Assets is posted at -0.39, Equity is -3.58 and Total Capital is -0.77. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of2.95.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 121.64 points at the first support level, and at 119.81 for the second support level. However, for the 1st resistance point, the stock is sitting at 124.95, and for the 2nd resistance point, it is at 126.44.
Ratios To Look Out For
For context, Axsome Therapeutics Inc’s Current Ratio is 1.57. In addition, the Quick Ratio stands at 1.51 and the Cash Ratio stands at 0.89. Considering the valuation of this stock, the price to sales ratio is 12.45, the price to book ratio is 84.17.
Transactions by insiders
Recent insider trading involved JEFFS ROGER, Director, that happened on Sep 02 ’25 when 13464.0 shares were sold. Director, JEFFS ROGER completed a deal on Sep 02 ’25 to buy 13464.0 shares. Meanwhile, Director JEFFS ROGER sold 20000.0 shares on Aug 27 ’25.
